The moves forecasted by the COT signals make them very adaptable to commodity based ETFs, writes And...
Biotech ETF Ripe for Short Sale
02/25/2011 7:00 am EST
Clinical trials aside, one popular biotech ETF has failed a recent technical trial. With key support broken, it now looks likely to continue even lower.
Shares of the Biotech HOLDRS Trust ETF (BBH) have now closed below support three times this week.
The $100.00 level had held as support since December 2010, though BBH did not participate in the strong market rally in early 2011.
The break of support leaves the shares vulnerable to further declines.
There is support at the $96.50 level, the lows reached on November 30, 3010, and then at $95.91, the 50% retracement level for the August 27, 2010-to-January 18, 2011 advance.
The 200-day moving average sits just above $96, and BBH is also now below its 50-day moving average, adding to the bearish short-term case.
By Frank Kollar of FibTimer.com
Related Articles on ETFS
The WisdomTree Europe Hedged Equity Fund (HEDJ) is an exchange-traded fund that provides investors w...
Funds that stick to a specific style make good core holdings — they establish your asset alloc...
The S&P 500 SPDR (SPY) has eked out a new high this week, notes Marvin Appel...